- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02528474
Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents
March 27, 2019 updated by: Yonsei University
Drug-coated balloon technology (DCB) has recently attracted considerable interest as a promising alternative treatment option, particularly in the setting of in-stent restenosis (ISR).
Optical coherence tomographic finding of restenosis lesions in drug-eluting stents (DESs) after Balloon Angioplasty with Two Different Paclitaxel-Coated Balloons will be compared between two paclitaxel-coated balloon devices; Pantera Lux™ and SeQuent® Please.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients ≥ 19 years old
- Patients eligible for percutaneous coronary intervention
- Single or more lesion(s) of restenosis requiring angioplasty in drug-eluting stent
- Reference vessel diameter of target lesion ≥2.5 mm
Exclusion Criteria:
- Cardiogenic shock
- Bifurcation lesion or totally occluded lesion
- Unprotected left main trunk lesion
- Allergies or hypersensitivities to antiplatelet, anticoagulation therapy, contrast media, or paclitaxel
- Heavy calcified (definite calcified lesions on angiogram) or extremely tortuous lesions
- Pregnant women or women with potential childbearing
- Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
- Inability to understand or read the informed content
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pantera Lux
|
Patient will be considered to be enrolled if ISR in DES was found by angiography.
After randomization, patients will be treated with Pantera Lux for treatment of ISR.
OCT will be performed just after balloon angioplasty for ISR lesion.
Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters.
Follow-up OCT at 9 month will be performed.
|
|
Active Comparator: SeQuent Please
|
Patient will be considered to be enrolled if ISR in DES was found by angiography.
After randomization, patients will be treated with SeQuent Please for treatment of ISR.
OCT will be performed just after balloon angioplasty for ISR lesion.
Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters.
Follow-up OCT at 9 month will be performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neointimal thickness & area
Time Frame: 9 months
|
measured by OCT analysis
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 30, 2015
Primary Completion (Actual)
April 20, 2017
Study Completion (Actual)
April 20, 2017
Study Registration Dates
First Submitted
July 31, 2015
First Submitted That Met QC Criteria
August 18, 2015
First Posted (Estimate)
August 19, 2015
Study Record Updates
Last Update Posted (Actual)
March 29, 2019
Last Update Submitted That Met QC Criteria
March 27, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-2015-0041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Infirmerie Protestante de LyonRecruitingCoronary Artery Bypass | Coronary Artery Disease(CAD) | Off Pump Coronary Artery Bypass Surgery | Hemodynamic Optimization | Hemodynamic Management | Off Pump Coronary Artery Bypass Graft | Coronary Artery Disease With Need for Bypass Surgery | NoradrenalineFrance
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
Istanbul Mehmet Akif Ersoy Educational and Training...Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Ege University; Istanbul... and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Coronary Bifurcation Lesion | Left Main Coronary Artery StenosisTurkey (Türkiye)
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCompletedCoronary Artery Disease (CAD) | Atherosclerosis of Coronary ArteryItaly
-
EBI Anti Sepsis BVCR2O B.V.Not yet recruitingCoronary Artery Disease (CAD) | Coronary Artery Bypass Graft Surgery(CABG)United States, Netherlands, Belgium, United Kingdom
-
University Medical Centre LjubljanaRecruitingCoronary Artery Disease With Myocardial InfarctionSlovenia
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Shunmei MedicalNot yet recruitingCalcified Coronary Artery Disease | Coronary Arterial DiseasePoland, France, Spain
-
OPCI Core Laboratories LLCNot yet recruitingCoronary Artery Disease (CAD) | Coronary Calcification | Coronary Calcified Disease | Coronary Calcified NodulesUnited States
Clinical Trials on balloon angioplasty with Pantera Lux
-
Biotronik FranceMedPass InternationalUnknownCoronary Artery Disease | High Bleeding Risk PatientsFrance
-
Cantonal Hospital of St. GallenUnknownRenal InsufficiencySwitzerland
-
Peking Union Medical College HospitalNot yet recruiting
-
King Abdullah International Medical Research CenterTerminatedDysfunctional Dialysis Arteriovenous FistulaSaudi Arabia
-
Singapore General HospitalSingapore Clinical Research InstituteUnknownStenosis of Arteriovenous Dialysis Fistula
-
Helsinki University Central HospitalCompletedVascular Access Complication | Restenosis, Vascular Graft | Dialysis Related Complications
-
Boris DzudovicMilitary Medical Academy, Belgrade, Serbia; Galen ResearchEnrolling by invitationChronic Thromboembolic Pulmonary HypertensionSerbia
-
Biotronik AGCompletedIn-stent Coronary Artery RestenosisGermany
-
Netherlands Heart FoundationBristol-Myers Squibb; Eli Lilly and Company; Boehringer Ingelheim; The Interuniversity...UnknownMyocardial Infarction | Coronary Artery DiseaseNetherlands
-
Henry Ford Health SystemBoston Scientific CorporationWithdrawn